In vitro activities of arylomycin natural-product antibiotics against Staphylococcus epidermidis and other coagulase-negative staphylococci

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1130-1134

  Smith, Peter A ^a   Powers, Michael E ^a   Roberts, Tucker C ^a   Romesberg, Floyd E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ARYLOMYCIN C 16; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SPSIB GENE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS CAPITIS; STAPHYLOCOCCUS CAPRAE; STAPHYLOCOCCUS COHNII; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS HOMINIS; STAPHYLOCOCCUS LUGDUNENSIS; STAPHYLOCOCCUS SAPROPHYTICUS; STAPHYLOCOCCUS WARNERI; STAPHYLOCOCCUS XYLOSUS;

ANTI-BACTERIAL AGENTS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; OLIGOPEPTIDES; STAPHYLOCOCCUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 79952353537     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01459-10     Document Type: Article

References (31)

1. Barros, E. M., N. L. Iorio, C. Bastos Mdo, K. R. dos Santos, and M. Giambiagi-deMarval. 2007. Species-level identification of clinical staphylococcal isolates based on polymerase chain reaction-restriction fragment length polymorphism analysis of a partial groEL gene sequence. Diagn. Microbiol. Infect. Dis. 59:251-257.
2. Bowker, K. E., P. Caspers, B. Gaucher, and A. P. MacGowan. 2009. In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 53:4949-4952.
3. Cheung, G. Y., and M. Otto. 2010. Understanding the significance of Staphylococcus epidermidis bacteremia in babies and children. Curr. Opin. Infect. Dis. 23:208-216.
4. Cole, J. R., et al. 2009. The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res. 37:D141-D145.
5. Dalbey, R. E., M. O. Lively, S. Bron, and J. M. van Dijl. 1997. The chemistry and enzymology of the type I signal peptidases. Protein Sci. 6:1129-1138. (Pubitemid 27260147)
6. De Buyser, M. L., A. Morvan, S. Aubert, F. Dilasser, and N. el Solh. 1992. Evaluation of a ribosomal RNA gene probe for the identification of species and subspecies within the genus Staphylococcus. J. Gen. Microbiol. 138:889-899.
7. Drancourt, M., and D. Raoult. 2002. rpoB gene sequence-based identification of Staphylococcus species. J. Clin. Microbiol. 40:1333-1338.
8. Edgar, R. C. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32:1792-1797. (Pubitemid 38832724)
9. Eliopoulos, G. M., et al. 1986. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 30:532-535.
10. Emori, T. G., and R. P. Gaynes. 1993. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin. Microbiol. Rev. 6:428-442.
11. Garrett, D. O., et al. 1999. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect. Control Hosp. Epidemiol. 20:167-170.
12. Guindon, S., and O. Gascuel. 2003. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst. Biol. 52:696-704.
13. John, M. A., C. Pletch, and Z. Hussain. 2002. In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci. J. Antimicrob. Chemother. 50:933-938.
14. Jones, R. N., D. M. Johnson, and M. E. Erwin. 1996. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob. Agents Chemother. 40:720-726.
15. Kulanthaivel, P., et al. 2004. Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I. J. Biol. Chem. 279:36250-36258.
16. Marshall, S. A., W. W. Wilke, M. A. Pfaller, and R. N. Jones. 1998. Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. Diagn. Microbiol. Infect. Dis. 30:205-214.
17. Noble, W. C., Z. Virani, and R. G. Cree. 1992. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 72:195-198.
18. Otto, M. 2009. Staphylococcus epidermidis - the "accidental" pathogen. Nat. Rev. Microbiol. 7:555-567.
19. Paetzel, M., J. J. Goodall, M. Kania, R. E. Dalbey, and M. G. Page. 2004. Crystallographic and biophysical analysis of a bacterial signal peptidase in complex with a lipopeptide-based inhibitor. J. Biol. Chem. 279:30781-30790.
20. Paetzel, M., A. Karla, N. C. Strynadka, and R. E. Dalbey. 2002. Signal peptidases. Chem. Rev. 102:4549-4580.
21. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
22. Planchon, S., et al. 2007. Proteomic analysis of cell envelope from Staphylococcus xylosus C2a, a coagulase-negative staphylococcus. J. Proteome Res. 6:3566-3580.
23. Rice, P., I. Longden, and A. Bleasby. 2000. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet. 16:276-277.
24. 2. J. Am. Chem. Soc. 129:15830-15838.
25. Schimana, J., et al. 2002. Arylomycins A and B, new biaryl-bridged lipopeptide antibiotics produced by Streptomyces sp. Tü 6075. I. Taxonomy, fermentation, isolation and biological activities. J. Antibiot. (Tokyo) 55:565-570.
26. Schwalbe, R. S., J. T. Stapleton, and P. H. Gilligan. 1987. Emergence of vancomycin resistance in coagulase-negative staphylococci. N. Engl. J. Med. 316:927-931.
27. Shah, M. M., et al. 2007. dnaJ gene sequence-based assay for species identification and phylogenetic grouping in the genus Staphylococcus. Int. J. Syst. Evol. Microbiol. 57:25-30. (Pubitemid 46152725)
28. Sieradzki, K., R. B. Roberts, D. Serur, J. Hargrave, and A. Tomasz. 1999. Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy. J. Clin. Microbiol. 37:39-44.
29. Smith, P. A., T. C. Roberts, and F. E. Romesberg. 2010. Broad spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations. Chem. Biol. 17:1223-1231.
30. Tamura, K., J. Dudley, M. Nei, and S. Kumar. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596-1599.
31. Wisplinghoff, H., et al. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.